Abstract
Subject Index
Adenovirus, 264–275
αvβ6-specific peptides, 111–120
Angiogenesis
biomarkers, 187–198
cyclic RGD peptides and, 101–109
NF-κB activity and, 278–289
prostate cancer and, 56–61, 209–219
rheumatoid arthritis and, 330–339
Antiatherosclerotic therapy, 291–300
Antibody-nanoparticle conjugations, 221–228
Antifolate-mediated augmentation, 305–317
AP39-TSC contrast agent, 330–339
Arginine-glycine-aspartate (RGD) peptides, 65–72
Atherosclerotic plaque, 291–300
Atlas-based segmentation, 35–43
Atorvastatin, 291–300
Atypical teratoid/rhabdoid tumors (AT/RTs), 199–207
Augmentation of protein expression, 305–317
Automated segmentation, of brain MRIs, 35–43
Background reduction, 303–304
Bicistronic vectors, 305–317
Biodistribution studies, 27–33
Bioluminescence imaging (BLI)
combined MRI strategy, 245–252
of integrin receptor-positive tumors, 101–109
NF-κB activity and, 278–289
Blood, umbilical cord, 166–177
Blood pool contrast agents, 45–53
BODIPY FL (boron-dipyrromethene), 341–352
Bone marrow, 166–177
Brain
MRI data, 35–43
tumor growth, 245–252
tumor metabolism, 199–207
Breast cancer
2D-3D image fusion monitoring of, 2–13
detection, 87–98
US-MRI registration technique for, 187–198
Cancer. See Carcinoma Capsid-labeling fusion, 264–275
Carbodiimide, 221–228
Carcinoma
breast, 2–13, 87–98, 187–198
ovarian, 264–275
pancreatic, 2–13
prostate, 15–24, 56–61, 209–219
Cathepsin B (CatB) imaging, 291–300
Cellular contrast, 129–138, 148–154, 166–177
Cellular immunotherapy, 15–24
Choroid plexus carcinoma (CPC), 199–207
Click chemistry, 221–228
Collagen-induced arthritis, in rats, 330–339
Combined BLI-MRI strategy, 245–252
Computed tomography (CT)
flat-panel volume, 2–13
multimodal imaging and, 87–98
photoacoustic, 96–97
single-photon emission, 58–60, 101–109
Computer-controlled, high-power LED light sources, 156–165
Conditionally replicative adenovirus (CRAd) imaging strategies, 264–275
Confocal microscopy, 15–24
Conjugation efficiency, 221–228
Contrast agents
blood pool, 45–53
endogenous, 129–138
iodine-containing, 2–13
for neurography, 319–327
See also Molecular imaging markers
Contrast-enhanced ultrasonography (CEUS), 187–198
[64Cu] Cu-CB-TE2A chelates, 111–120
[64Cu] Cu-DOTA chelates, 111–120
Cy5.5
cell staining with, 65–72
labeled antibodies, 2–13
toxicity of, 341–352
Cyclic RGD peptides, 101–109
Cypate, 341–352
Cytotoxic T lymphocytes (CTLs), 230–237
Cytotoxicity, 132–138
DHFR/MTX system, 305–317
Dihydrofolate reductase (DHFR) protein, 305–317
Diseased tissue imaging, 45–53
Drug delivery vehicles, 221–228
Dual-contrast MRI, 254–263
See also Magnetic resonance imaging
Dual-imaging modality-labeled capsid, 264–275
Dual-modality probes, 87–98, 264–275
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), 187–198
[18F]fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil (18F-FEAU), 230–237
[18F]fluorobenzoyl, 111–12018
F-FEAU PET-CT imaging, 230–237
Electro-optical coupling, 74–85
Embryonic stem cells, 166–177
Endogenous contrast agents, 129–138
Endothelin A receptors (ETARs), 27–33
Extra domain B (ED-B) fibronectin, 330–339
Fast low-angle positive-contrast steadystate free precession (FLAPS) labeling of GFP cells, 148–154
MRI, 254–263
Fast retrograde axonal transport, 319–327
Flat-panel volume computed tomography (fpVCT), 2–13
Flk1-targeted enhanced ultrasound imaging, 209–219
Fluorescein, 341–352
Fluorescence imaging (FLI)
of fast retrograde axonal transport, 319–327
to monitor viral replication, 264–275
Fluorescence microscopy
cellular immunotherapy and, 15–24
of integrin receptor-positive tumors, 101–109
Fluorescence reflectance imaging (FRI), 27–33
Fluorescence-guided surgery, 156–165
Fluorescent imaging probes, 27–33
Fluorescently labeled contrast agent, 319–327
Fluorescent/nuclear imaging tags, 264–275
Fluorophore
labeled cells, 15–24
toxicity, 341–352
Food and Drug Administration (FDA), 341–352
Gamma scintigraphy, 101–109
Gaussia princeps luciferase (Gluc), 278–289
Genetically engineered prostate cancer model, 209–219
Glioblastoma, 245–252
Gluc activity, 278–289
Glucosamine, 291–300
Gradient-recalled echo (GRE) imaging methods, 254–263
Green fluorescent protein (GFP) expressing cells, 148–154, 166–177
High-power, computer-controlled LED light sources, 156–165
HSV1-tk-expressing T cells, 230–237
Human serum albumin (HSA), 65–72
Human umbilical cord blood mononuclear cells (hUCBCs), 166–177
Image fusion, 2–13
Image-guided surgery, 156–165
Imaging probes
AP39-TSC conjugate as, 330–339
dual-modality, 87–98
fluorescent, 27–33
RGD-HSA conjugates as, 65–72
toxicity of, 341–352
Immunotherapy, 15–24
In vivo imaging
dual-modality probes for, 87–98
of NF-κB-activity, 278–289
pharmacodynamic, 140–147
of retrograde neuronal transport, 319–327
of rheumatoid arthritis, 330–339
Indocyanine green (ICG), 341–352
Infectivity-enhanced oncolytic adenovirus, 264–275
Inflammation, in atherosclerotic pathology, 291–300
Integrin αvβ6, 111–120
Integrin receptor-positive tumors, 101–109
Internal ribosome entry site (IRES) element, 305–317
Intracellular contrast, 129–138, 148–154
Intravenous infusion, of HSV1-tk-expressing T cells, 230–237
IR-820,45–53
Iron oxide nanoparticles, 65–72
See also Superparamagnetic iron oxide Iron uptake, 129–138
Joints, and rheumatoid arthritis, 330–339
Labeled cells 64Cu, 111–120
iron oxide, 148–154, 166–177
magnetic, 166–177
near-infrared dye DiD, 15–24
prostate cancer and, 15–24
tracking with FLAPS MRI, 254–263
Light-emitting diode (LED) light sources, 156–165
Live cell imaging, 129–138
Local magnetic susceptibility (LMS) altering agents, 254–263
Luciferase-ODD, 140–147
Macrophages, 291–300
MagA expression, 129–138
Magnetic resonance imaging (MRI) automated segmentation of, 35–43
of cells overexpressing MagA, 129–138
combined BLI strategy, 245–252
compatible PET detectors, 74–85
dual-contrast, 254–263
of magnetically labeled stem cells, 166–177
nuclear combination imaging, 89–91
of orthotopic brain tumors, 199–207
positive and negative contrast, 148–154
prostate cancer and, 57–58
US coregistration, 187–198
Magnetic resonance spectroscopy (MRS) of orthotopic brain tumors, 199–207
prostate cancer and, 57–58
Magnetically labeled stem cells, 166–177
Magnetosomes, 129–138
Mammary carcinoma, 2–13
See also Breast cancer
Methotrexate (MTX) treatment, 305–317
Microbubbles, 209–219
MicroPET imaging, 111–120
Microscopy
confocal, 15–24
fluorescence, 15–24, 101–109
Molecular diagnosis, 209–219
Molecular imaging markers for ovarian cancer, 264–275
for prostate cancer, 209–219
See also Contrast agents
Monitoring, of NF-κB activation, 278–289
Mononuclear cells, 166–177
MRI/optical combination imaging, 93–95
MRI/PET system designs, 74–85
Multimodal imaging
combined BLI-MRI strategy, 245–252
of integrin receptor-positive tumors, 101–109
nuclear/MRI combination, 89–91
nuclear/optical combination, 91–93
optical/MRI combination, 93–95
for ovarian cancer, 264–275
for prostate cancer, 56–61
US-MRI registration technique, 187–198
for in vivo imaging, 87–98
Murine
atheromata, 291–300
brain MRI segmentation, 35–43
brain tumor growth, 245–252
brain tumor metabolism, 199–207
collagen-induced arthritis, 330–339
embryonic stem cells, 166–177
preclinical tumor model, 187–198
prostate cancer model, 209–219
Muscle injury imaging, 45–53
Nanoparticle-antibody conjugations, 221–228
Nanoparticles, 65–72
See also Superparamagnetic iron oxide
Natural killer (NK) cells, 15–24
Near-infrared (NIR) fluorescenceguided surgery, 156–165
Near-infrared blood pool contrast agents, 45–53
Near-infrared fluorescence (NIRF)
imaging
of CatB proteolytic enzyme activity, 291–300
flat-panel volume CT and, 2–13
of integrin receptor-positive tumors, 101–109
with IR-820, 45–53
RGD-HSA conjugates and, 65–72
of rheumatoid arthritis, 330–339
Negative contrast MRI, 148–154
Neuroblastoma (N2A) cells, 129–138
Neurography, 319–327
NF-Gluc reporter, 278–289
Nonhuman primates, and repetitive PET-CT imaging, 230–237
Noninvasive imaging
of adoptively transferred T cells, 230–237
based on TTc, 319–327
combined BLI-MRI strategy for, 245–252
of ovarian cancer virotherapy, 264–275
Nonlinear atlas-based segmentation, 41–42
Nontarget tissue uptake, 303–304
Nontoxic C fragment of tetanus toxin (TTc), 319–327
Nuclear factor κB (NF-κB) activation, 278–289
Nuclear/fluorescent imaging, 264–275
Nuclear/MRI combination imaging, 89–91
Nuclear/optical combination imaging, 91–93
ODDLuc reporter, 140–147
ODD-luciferase, 140–147
Off-resonance positive contrast (ORPC) imaging, 254–263
Optical imaging
of cellular immunotherapy, 15–24
LED light sources for, 156–165
MRI combined, 93–95
nuclear combined, 91–93
prostate cancer and, 60–61
Oregon Green, 341–352
Organic fluorophores, 341–352
Orthotopic brain tumors, 199–207
Ovarian cancer virotherapy, 264–275
Oxygen-dependent destruction domain (ODD), 140–147
Pancreatic carcinoma, 2–13
Parkinson disease, 166–177
Pediatric brain tumors, 199–207
Peptide(s)
arginine-glycine-aspartate, 65–72
radiolabeled, 101–109
for targeted integrins, 111–120
Peripheral nerve tissue, 319–327
PET-CT imaging, 230–237
PET-MRI dual-modality probes, 89–91
PET/MRI system designs, 74–85
Pharmacodynamic imaging, 140–147
Photoacoustic computed tomography, 96–97
Plaque inflammation, atherosclerotic, 291–300
Positive contrast MRI, 148–154
Positron emission tomography (PET) αvβ6-specific peptides and, 111–120
CT combined, 230–237
detectors, MRI-compatible, 74–85
MRI dual-modality probe, 89–91
prostate cancer and, 58–60
Probes. See Imaging probes Prostate cancer
molecular imaging and, 56–61, 209–219
optical imaging and, 15–24, 60–61
Proteasome inhibition, 140–147
Protein expression, modulation of, 305–317
Prussian blue stain, 129–138, 150–151
QD-based dual-modality probes, 93
Rapamycin treatment, 305–317
Repetitive PET-CT imaging, 230–237
Reporter system, NF-κB-based, 278–289
Retrograde axonal transport, 319–327
RGD-HSA conjugates, 65–72
Rheumatoid arthritis, 330–339
Rhodamine 110, 341–352
Rhodamine 6G (Rh6G), 341–352
Scintigraphy, 101–109
Segmentation, of brain MRI, 35–43
Semi-automated image fusion, 2–13
Signal intensity, 27–33
Signal to background-ratio (SBR), 35–43, 303–304
Single-photon emission computed
tomography (SPECT)
of integrin receptor-positive tumors, 101–109
prostate cancer and, 58–60
Solid-state photomultipliers, 74–85
Spatial colocalizaton, of VEGFR2
expression, 187–198
SPECT-CT dual-modality probes, 91–93
sr39HSV1-tk reporter gene, 230–237
Steady-state free precession (SSFP) imaging, 254–263
Stem cells, 166–177
Superparamagnetic iron oxide (SPIO)
cell labeling with, 148–154, 166–177, 254–263
nanoparticles, antibodies and, 221–228
Surgery, fluorescence-guided, 156–165
Susceptibility-shifting agents, 254–263
T cells, 230–237
Targeted microbubble-enhanced US imaging, 209–219
Targeted nanoparticles, 221–228
Texas red, 341–352
Three-dimensional, high-resolution, fpVCT, 2–13
tk-mRFP1
fusion, 264–275
T-lymphocyte imaging, 230–237
Tokyo Green, 341–352
Toxicity, fluorophore, 341–352
Translational modulation of proteins, 305–317
Tumor(s)
angiogenesis and invasiveness of, 278–289
combined BLI-MRI strategy for, 245–252
molecular diagnosis of, 209–219
multimodal imaging of, 101–109, 187–198
natural killer cell therapy, 15–24
orthotopic mouse brain, 199–207
RGD-HSA conjugate targeting probes, 65–72
26S proteasome inhibition, 140–147
2D-3D image fusion, 2–13
Ultrasmall superparamagnetic iron oxide (USPIO), 148–154
Ultrasonography (US)
Flk1-targeted microbubbleenhanced, 209–219
MRI coregistration, 187–198
Umbilical cord blood, 166–177
US-MRI registration technique, 187–198
Vascular endothelial growth factor receptor 2
(VEGFR2), 187–198
Vascular endothelial growth factor receptor (Flk1), 209–219
Vertical cavity surface emitting laser (VCSEL), 74–85
Virotherapy, 264–275
Western diet, 291–300
Xenografts
αvβ6, 111–120
ODDLuc tumor, 140–147
orthotopic tumor, 2–13, 199–207
prostate tumor, 15–24, 56–61
subcutaneous tumor, 101–109
Author Index
Achilefu, Samuel, 101
Akers, Walter J., 101
Alauddin, Mian, 230
Alford, Raphael, 341
Alvarez, Ronald D, 264
Alves, Frauke, 2
Anderson, Carolyn J., 111
Badr, Christian E., 278
Bahadur, Ali N., 45
Banerjee, Debabrata, 305
Bauman, Glenn S., 209
Bertino, Joseph R., 305
Bloch, Sharon, 101
Blüml, Stefan, 199
Boddington, Sophie, 15
Bollard, Catherine M., 230
Boltze, Johannes, 166
Borne, Agatha, 230
Borovjagin, Anton V., 264
Bradner, James E., 140
Brammer, David, 230
Bredow, Sebastian, 319
Bremer, Christoph, 27
Bygrave, Michael, 209
Chen, Kai, 65
Chen, Xiaoyuan, 65, 87
Cheney, Philip P., 101
Chisholm, Gary B., 45
Choyke, Peter L., 341
Ciocan, Razvan, 156
Collins, Lynne, 245
Cooper, Laurence J.N., 230
Curiel, David T., 264
Daldrup-Link, Heike E., 15
Davis, Tina N., 140
Decker, William K., 230
Dhanvantari, Savita, 129
Dharmakumar, Rohan, 148, 254
Dijkstra, Jouke, 35
Dotti, Gianpietro, 230
Douglas, Joanne T., 264
Duberman, Josh, 341
Dullin, Christian, 2
Ebert, Bernd, 330
Edwards, W. Barry, 101
Elias, Drew R., 221
Erdreich-Epstein, Anat, 199
Fan, Zhaoyang, 148
Fenster, Aaron, 209
Ferdani, Riccardo, 111
Figueredo, Rene, 129
Finlay, Jonathan L., 199
Foster, Paula, 129
Frangioni, John V., 156, 303
Gagnon, M. Karen J., 111
Garbow, Joel R., 245
Gelovani, Juri G., 230, 319
Gemeinhardt, Ines, 330
Gemeinhardt, Ole, 330
Gioux, Sylvain, 156
Goldhawk, Donna E., 129
Gonzalez, Carlos, 230
Gonzalez-Gomez, Ignacio, 199
Gore, John C., 187
Grabbe, Eckhardt, 2
Greenberg, Norman M., 209
Grune, Tilman, 166
Gupta, Sunil, 156
Gutzeit, Cindy, 166
Harutyunyan, Ira, 199
Hau, Susann, 166
Hausner, Sven H., 111
Heindel, Walter, 27
Henning, Tobias D., 15
Hild, Katharina, 166
Hill, G. Craig, 341
Höltke, Carsten, 27
Hostetter, Daniel, 15
Icyuz, Mert, 264
Izawa, Jonathan I., 209
Jackson, James, 230
Jadvar, Hossein, 56
Jeong, Sang-Wuk, 291
Jha, Priyanka, 15
Johansson, Magnus, 15
Jost, Sarah C., 245
Jung, Tobias, 166
Keller, Charles, 45
Kianzad, Vida, 156
Kim, Dong-Eog, 291
Kim, Eo-Jin, 291
Kim, Jeong-Yeon, 291
Kim, Woo Kyung, 291
Kimball, Kristopher J., 264
Kimbrel, Erin A., 140
Klibanov, Alexander, 209
Knopp, Christiane, 15
Kobayashi, Hisataka, 341
Koktzoglou, Ioannis, 254
Kopka, Klaus, 27
Kornblau, Steven, 230
Koropatnick, Jim, 129
Krell, Hans-Willi, 2
Kressel, Jenny, 166
Krieger, Mark D., 199
Kukis, David L., 111
Kung, Andrew L., 140
Laforest, Richard, 101
Le Roux, Lucia G., 319
Lechleiter, James D., 45
Lee, Seulki, 87
Lemaire, Claude, 129
Levin, Craig S., 74
Li, Debiao, 148, 254
Li, Jing, 264
Licha, Kai, 330
Loveless, Mary E., 187
Lyshchik, Andrej, 187
Macdonald, Rainer, 330
Marini, Frank, 230
Marshall, John F., 111
Martinez, Carlo O., 45
Mascheri, Nicole, 148
Mawlawi, Osama, 230
Mayer-Kuckuk, Philipp, 305
McCreary, Cheryl R., 129
McGirr, Rebecca, 129
McManus, Linda M., 45
Meier, Reinhard, 15
Melendez, Elizabeth, 199
Menon, Lata G., 305
Michalek, Joel E., 45
Mishra, Prasun J., 305
Mishra, Pravin J., 305
Missbach-Guentner, Jeannine, 2
Moussa, Madeleine, 209
Müller, Friedemann, 2
Müller, Tina, 15
Najjar, Amer, 230
Napp, Joanna, 2
Nelson, Marvin D., Jr., 199
Niers, Johanna M., 278
Noske, David P., 278
Ogawa, Mikako, 341
Oketokoun, Rafiou, 156
Olcott, Peter D., 74
Paolillo, Vincenzo, 230
Peng, Hao, 74
Piwnica-Worms, David, 245
Prajapati, Suresh I., 45
Prato, Frank S., 129
Regino, Celeste, 341
Reiber, Johan H.C., 35
Reich, Doreen, 166
Reinhart, Verena, 15
Reynolds, C. Patrick, 199
Rivera, Angel A., 264
Rosol, Michael, 199
Saini, Vaibhav, 264
Savoldo, Barbara, 230
Schäfers, Michael, 27
Scheenstra, Alize E.H., 35
Schellingerhout, Dawid, 291, 319
Schirner, Michael, 330
Schnorr, Jörg, 330
Schober, Otmar, 27
Shireman, Paula K., 45
Shon, Soo-Min, 291
Shpall, Elizabeth J., 230
Siegal, Gene P., 264
Sieland, Katharina, 166
Simpson, Haley M., 341
Sinha, Tuhin K., 187
Sista, Akhislesh, 15
Smbatyan, Goar, 199
Smith, Amanda, 230
Stanecki, Catherine E., 111
Steiner, David, 230
Stroh, Albrecht, 166
Sutcliffe, Julie L., 111
Tannous, Bakhos A., 278
Taupitz, Matthias, 330
Tavri, Sidhartha, 15
Thompson, R. Terry, 129
Thorek, Daniel L.J., 221
Tian, Mei, 230
Tietze, Lutz-F., 2
Tjon-Kon-Fat, Lee-Ann, 278
Travers, Sarah, 245
Tsaftaris, Sotirios A., 254
Tsourkas, Andrew, 221
Uthamanthil, Rajesh, 230
Valiyeva, Fatma, 209
van de Ven, Rob C.G., 35
van den Maagdenberg, Arn M.J.M., 35
van der Weerd, Louise, 35
VanBrocklin, Henry F., 55
Vater, Axel, 330
Voigt, Jan, 330
Vollmer, Sonja, 330
Waldeck, Jens, 27
Wang, Fen, 209
Wels, Winfreid S., 15
Whisenant, Jennifer G., 187
Wilson, Kevin, 187
Wu, Isabel Q., 45
Wu, Shengyong, 148
Wurdinger, Thomas, 278
Xie, Jin, 65
Xu, Baogang, 101
Xu, JingYing, 199
Xuan, Jim W., 209
Yankeelov, Thomas E., 187
Ye, Yunpeng, 101
Zhang, Zhuoli, 148, 254
Zheng, Wei, 45
Zhu, Zeng B., 264
Zientkowska, Marta, 2
Zimmer, Claus, 166
Zinn, Kurt R., 264